Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology

WEST LAFAYETTE, Ind., Oct. 4, 2011 /PRNewswire/ — Kylin Therapeutics, Inc., a
leading second-generation RNAi company, announced today that it has received a
notice of allowance from United States Patent and Trademark Office (USPTO) for
its second U.S. patent application. This newly allowed patent broadly covers new
therapeutic RNA technology, as well as expanded areas on Kylin’s proprietary
nanoparticle technology platform, “pRNA” (“packaging RNA”). This new
intellectual property covers multi-valent RNA structures broadly encompassing:
tissue targeting, aptamer binding, receptor-mediated endocytosis, and RNA
interference. “We continue to be gratified that the USPTO recognizes pRNA as an
entirely unique platform in the crowded RNAi intellectual property space,” said
J. Eric Davis, J.D., President and Chief Executive Officer of Kylin
Therapeutics, Inc.

Upon issuance, this will be Kylin’s second U.S. patent. Along with its other
issued and granted pRNA patents in Europe, Australia, and the United States,
Kylin believes that this seminal patent family represents rare “new ground” in
the field of RNAi and the delivery of therapeutic RNA. Kylin has a total of five
patent families, with several other applications in the pipeline. “The
unexpected, pharmacologically robust nature of the pRNA platform continues to
allow Kylin to claim more ground in areas such as RNAi and tissue-specific
targeting,” said Homer Pearce, Ph.D., Director and Chairman of Kylin’s
Scientific Advisory Board.

Kylin’s pRNA intellectual property estate is based upon the innovative
discoveries of Peixuan Guo, Ph.D., and others at Kylin, on the design and
creation of novel, therapeutically relevant RNA molecules. These molecules can
be engineered as RNA multiplexes that function as RNAi-inducing DICER substrates
and tissue-targeting modalities, and they can be used systemically and
discretely without additional delivery components. Kylin has continued and
expanded upon the work of Dr. Guo, demonstrating the improved pharmacokinetics
of pRNA molecules in several relevant in vivo model systems, primarily in
cancer.

“The pRNA patents are a result of Kylin’s and Dr. Guo’s visionary efforts to
borrow from nature and create novel, therapeutically superior RNA molecules,”
said Davis. “We continue to believe this is an entirely new intellectual
property landscape in the field of RNA-based therapeutics, one that is distinct
and protectable from other patents in the RNAi and antisense fields.”

Following a Notice of Allowance, the process resulting in final issuance of a
patent involves a number of administrative steps that are typically completed in
a few months.

About Kylin Therapeutics

Kylin Therapeutics, Inc., a second-generation RNAi company, employs a
revolutionary RNA nanoparticle technology platform called “pRNA” to exploit the
enormous potential of RNA interference (RNAi) for treatment of many common
diseases. This visionary platform has enormous potential to meet the huge market
opportunity for treating cancer and other diseases with RNA-based therapeutics.
The unique capabilities of the platform have enabled Kylin to overcome the most
significant challenges in the development of RNA-based therapies.

Contact: Eric Davis, Kylin Therapeutics, 919-386-9694,
edavis@kylintherapeutics.com, http://www.kylintherapeutics.com

This press release was issued through eReleases(R). For more information, visit
eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE Kylin Therapeutics, Inc.